Who has been buying Prestige Biopharma stock?

1 distinct insiders have filed 3 disclosed insider purchases in Prestige Biopharma (950210), most recently on 2026-07-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Prestige Biopharma have?

Prestige Biopharma has 3 buy-side and 0 sell-side disclosures on record, covering ₩73M ($51K) in total reported value, spanning 2024-09-27 to 2026-07-02.

Where does StockDrifts get Prestige Biopharma insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Prestige Biopharma 950210

Company

프레스티지바이오파마Prestige Biopharma

Insiders

Buys

Total Value

₩73M ($51K)

Avg Return

-3.74%

Last Filing

2026-07-02

Prestige Biopharma (950210) has 3 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩73M ($51K) in reported transaction value. The earliest filing StockDrifts holds for Prestige Biopharma is dated 2024-09-27; the most recent is 2026-07-02. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -3.74%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-07	BUY	Market Buy	박소연 Soyeon Park	Chairman	1.6K	₩6,600	-0.6%	₩11M ($8K)
2026-08-06	BUY	Market Buy	박소연 Soyeon Park	Chairman	2.2K	₩6,610	-0.8%	₩15M ($10K)
2026-08-05	BUY	Market Buy	박소연 Soyeon Park	Chairman	3.0K	₩6,500	+0.9%	₩20M ($14K)
2026-08-04	BUY	Market Buy	박소연 Soyeon Park	Chairman	3.5K	₩6,500	+0.9%	₩23M ($16K)
2026-07-31	BUY	Market Buy	박소연 Soyeon Park	Chairman	4.4K	₩6,400	-0.9%	₩28M ($19K)
2026-07-30	BUY	Market Buy	박소연 Soyeon Park	Chairman	4.1K	₩5,720	+10.8%	₩23M ($16K)
2026-07-29	BUY	Market Buy	박소연 Soyeon Park	Chairman	5.5K	₩5,550	+14.2%	₩31M ($21K)
2026-07-28	BUY	Market Buy	박소연 Soyeon Park	CEO	3.9K	₩5,550	+15.3%	₩22M ($15K)
2026-07-28	BUY	Market Buy	박소연 Soyeon Park	Chairman	3.9K	₩5,550	+14.2%	₩22M ($15K)
2026-07-27	BUY	Market Buy	박소연 Soyeon Park	Chairman	3.4K	₩5,610	+13.0%	₩19M ($13K)
2026-07-27	BUY	Market Buy	박소연 Soyeon Park	CEO	3.4K	₩5,610	+14.1%	₩19M ($13K)
2026-07-27	BUY	장외매수	박소연 Soyeon Park	CEO	8.6K	₩5,610	+14.1%	₩48M ($34K)
2026-07-27	BUY	장외매수	박소연 Soyeon Park	Chairman	8.6K	₩5,610	+13.0%	₩48M ($34K)
2026-07-24	BUY	Market Buy	박소연 Soyeon Park	Chairman	2.4K	₩5,250	+20.8%	₩13M ($9K)
2026-07-24	BUY	Market Buy	박소연 Soyeon Park	CEO	2.4K	₩5,250	+21.9%	₩13M ($9K)
2026-07-02	BUY	Market Buy	김 마이클 진우 Kim Michael Jinwoo	vice president	2.0K	₩6,430	-11.7%	₩13M ($9K)
2026-07-02	BUY	Market Buy	김 마이클 진우 Kim Michael Jinwoo	vice president	400	₩6,430	-0.5%	₩3M ($2K)
2026-06-26	BUY	Market Buy	김 마이클 진우 Kim Michael Jinwoo	vice president	580	₩5,910	+8.3%	₩3M ($2K)
2026-06-26	BUY	Market Buy	김 마이클 진우 Kim Michael Jinwoo	vice president	2.9K	₩5,910	+2.4%	₩17M ($12K)
2026-06-25	BUY	Market Buy	김 마이클 진우 Kim Michael Jinwoo	vice president	1.4K	₩6,170	+3.7%	₩9M ($6K)
2026-06-25	BUY	Market Buy	김 마이클 진우 Kim Michael Jinwoo	vice president	7.0K	₩6,170	-1.9%	₩43M ($30K)
2025-02-10	BUY	시간외매매	옥타바펀드리미티드 Octava Fund Limited	-	250.0K	₩15,000	-23.0%	₩3.8B ($2.6M)
2024-09-27	BUY	신규선임	TAN TING YONG	Other non-executive directors	6.0K	₩13,980	-17.4%	₩84M ($58K)

Frequently asked questions

Who has been buying Prestige Biopharma stock?: 1 distinct insiders have filed 3 disclosed insider purchases in Prestige Biopharma (950210), most recently on 2026-07-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Prestige Biopharma have?: Prestige Biopharma has 3 buy-side and 0 sell-side disclosures on record, covering ₩73M ($51K) in total reported value, spanning 2024-09-27 to 2026-07-02.
Where does StockDrifts get Prestige Biopharma insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Prestige Biopharma. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.